Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • sjm
    Member
    • Nov 2009
    • 27

    #1

    many biological replicates - 'traditional' statistics vs Cuffdiff or DESeq/edgeR?

    I've read the discussions from Simon Anders and Lior Pachter intensively on these forums and understood them as best I can without extensive graduate training in mathematics or statistics :-) I grasp that correctly modeling the dispersion between biological replicates for a given treatment condition is vital for comparisons of gene expression between different treatment conditions, and that is more challenging for lower numbers of replicates.

    Before I was aware of Cuffdiff or DESeq (and actually before Cuffdiff came out), I aligned RNASeq reads using tophat and cufflinks to gain FPKM values on a 'gene-level' basis (I wasn't interested in individual isoforms). I had 6-8 biological replicates per condition, and used a traditional statistics program (Partek Genomics Suite in this case) to determine p-values between conditions and to determine a false discovery rate.

    I am in the process of comparing this approach to edgeR / DESeq to see whether comparisons between groups are generally similar. However, is there an 'a prior' statistical/mathematical reason why comparing FPKM-type data (for which, in my hands, the variance between biological replicates is normally distributed AND the variance appears to be higher when the FPKM is lower, reasonably suggesting more variance with lower read counts) between conditions is invalid or misleading?

    Thanks in advance for any thoughts.

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
42 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
32 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
44 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
45 views
0 reactions
Last Post SEQadmin2  
Working...